NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.2045 +0.01 (+5.14 %)
(As of 01/17/2019 04:00 PM ET)
Previous Close$0.1933
Today's Range$0.1855 - $0.2080
52-Week Range$0.17 - $2.65
Volume1.63 million shs
Average Volume6.15 million shs
Market Capitalization$13.15 million
P/E Ratio-0.25
Dividend YieldN/A
Beta1.07
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive GNMX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMX
Previous SymbolNASDAQ:MDGN
CUSIPN/A
Phone610-254-4201

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.52 per share

Profitability

Net Income$-34,710,000.00

Miscellaneous

Employees17
Market Cap$13.15 million
OptionableOptionable

Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions

What is Aevi Genomic Medicine's stock symbol?

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine Inc (NASDAQ:GNMX) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History.

When is Aevi Genomic Medicine's next earnings date?

Aevi Genomic Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Aevi Genomic Medicine.

What is the consensus analysts' recommendation for Aevi Genomic Medicine?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aevi Genomic Medicine in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aevi Genomic Medicine.

Has Aevi Genomic Medicine been receiving favorable news coverage?

Media coverage about GNMX stock has been trending negative on Thursday, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aevi Genomic Medicine earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Aevi Genomic Medicine's key competitors?

Who are Aevi Genomic Medicine's key executives?

Aevi Genomic Medicine's management team includes the folowing people:
  • Mr. Michael F. Cola, CEO, Pres & Director (Age 59)
  • Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)
  • Dr. Garry A. Neil, Chief Scientific Officer (Age 65)
  • Ms. Colleen Anderson, VP of Clinical Operations
  • Dr. Rick Couch, VP of Chemistry, Manufacturing & Controls

How do I buy shares of Aevi Genomic Medicine?

Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aevi Genomic Medicine's stock price today?

One share of GNMX stock can currently be purchased for approximately $0.2045.

How big of a company is Aevi Genomic Medicine?

Aevi Genomic Medicine has a market capitalization of $13.15 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.

What is Aevi Genomic Medicine's official website?

The official website for Aevi Genomic Medicine is http://www.aevigenomics.com.

How can I contact Aevi Genomic Medicine?

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]


MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Backdoor Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel